Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 1: eradication of Helicobacter in the cachexia of idiopathic parkinsonism

Helicobacter. 2005 Aug;10(4):267-75. doi: 10.1111/j.1523-5378.2005.00331.x.

Abstract

Background: Neuronal damage in idiopathic parkinsonism may be in response to ubiquitous occult infection. Since peptic ulceration is prodromal, Helicobacter is a prime candidate.

Aim: To consider the candidature of Helicobacter in parkinsonism with cachexia.

Methods: We explore the relationship between being underweight and inflammatory products in 124 subjects with idiopathic parkinsonism and 195 controls, and present the first case-series evidence of efficacy of Helicobacter eradication, in parkinsonism advanced to the stage of cachexia.

Results: Association of a low body mass index with circulating interleukin-6 was specific to parkinsonism (p = .002), unlike that with antibodies against Helicobacter vacuolating-toxin and cytotoxicity-associated gene product (p < .04). Marked reversibility in both cachexia and disability of idiopathic parkinsonism followed Helicobacter heilmannii eradication in one case, Helicobacter pylori eradication in another, follow-up being > or = 3.5 years. The latter presented with postprandial bloating, and persistent nausea: following eradication, radioisotope gastric-emptying returned towards normal, and upper abdominal symptoms regressed. Reversibility of their cachexia/disability contrasts with the outcome of anti-Helicobacter therapy where eradication repeatedly failed (one case), and in non-Helicobacter gastritis (three cases). Anti-parkinsonian medication remained constant. Intestinal absorption and barrier function were normal in all.

Conclusion: Categorization, according to presence or absence of Helicobacter infection, was a useful therapeutic tool in late idiopathic parkinsonism.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Anti-Bacterial Agents / therapeutic use*
  • Cachexia / drug therapy
  • Cachexia / etiology*
  • Cachexia / microbiology*
  • Cachexia / physiopathology
  • Chronic Disease
  • Female
  • Helicobacter Infections / complications*
  • Helicobacter Infections / drug therapy*
  • Helicobacter Infections / immunology
  • Helicobacter pylori / drug effects*
  • Humans
  • Inflammation / complications*
  • Male
  • Middle Aged
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / etiology*
  • Parkinson Disease / microbiology*
  • Parkinson Disease / physiopathology
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents